Pharmaceutical / Biotechnology - Drug Delivery Systems
Strategic Profile
Nanexa applies a two-part business model in which the company develops its own product projects, and also enters into cooperation agreements with external pharmaceutical companies for their product projects. The company has collaborations with Novo Nordisk and AstraZeneca for the development of pharmaceutical products with active substances.
Cyborg Score Rationale
Nanexa achieved positive results in the company's Phase I study for NEX-22, long acting GLP-1, in type 2 diabetes. Recent data demonstrates that the ALD platform PharmaShell® improves the pharmacokinetic profile of semaglutide injections with significantly smoother plasma concentration curve that could mitigate many common side effects of GLP-1 drugs. Strong partnerships and proprietary technology position it well in the high-growth GLP-1 market.
Top Insights
Recent positive Phase I data for NEX-22 (one-month liraglutide formulation) demonstrates clinical viability with well-tolerated dosing in type 2 diabetes patients
PharmaShell® technology shows demonstrable improvement in GLP-1 pharmacokinetics, potentially addressing common side effects of blockbuster GLP-1 drugs
Dual revenue model combining proprietary product development with technology licensing (Novo Nordisk, AstraZeneca partnerships) provides financial diversification
Platform applicability extends beyond diabetes to cancers, cardiovascular, and psychiatric disorders, indicating substantial market expansion potential
Named Competitors
Long-acting GLP-1 formulations — Leading GLP-1 drug developer with semaglutide and liraglutide portfolios
Injectable drug delivery systems — Pharmaceutical conglomerate developing advanced drug delivery platforms
Depot formulation technologies — Competitors developing alternative long-acting injectable delivery systems
(November 2025) Phase I study announces positive results for NEX-22 long-acting GLP-1 formulation in type 2 diabetes
(October 2024) Partnership agreement with pharma company covering development of up to five compounds; $3M upfront plus up to $500M in milestone payments
Open the full interactive Nanexa AB report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.